3 Buy-Rated Dividend Stocks
PDL BioPharma (NASDAQ: PDLI) shares currently have a dividend yield of 8.10%. PDL BioPharma, Inc. engages in intellectual property asset management and patent portfolio and related assets investment activities. The company has a P/E ratio of 5.10. Currently there are no analysts that rate PDL BioPharma a buy, no analysts rate it a sell, and 4 rate it a hold. The average volume for PDL BioPharma has been 1,925,400 shares per day over the past 30 days. PDL BioPharma has a market cap of $1.0 billion and is part of the drugs industry. Shares are up 3.4% year to date as of the close of trading on Wednesday. TheStreet Ratings rates PDL BioPharma as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, increase in net income and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Highlights from the ratings report include:
- The revenue growth came in higher than the industry average of 7.0%. Since the same quarter one year prior, revenues rose by 18.2%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
- Compared to where it was a year ago today, the stock is now trading at a higher level, reflecting both the market's overall trend during that period and the fact that the company's earnings growth has been robust. Turning our attention to the future direction of the stock, it goes without saying that even the best stocks can fall in an overall down market. However, in any other environment, this stock still has good upside potential despite the fact that it has already risen in the past year.
- PDL BIOPHARMA INC has improved earnings per share by 41.7% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, PDL BIOPHARMA INC increased its bottom line by earning $1.47 versus $1.15 in the prior year. This year, the market expects an improvement in earnings ($1.70 versus $1.47).
- The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Biotechnology industry. The net income increased by 26.9% when compared to the same quarter one year prior, rising from $38.94 million to $49.41 million.
- Net operating cash flow has increased to $51.59 million or 14.28% when compared to the same quarter last year. The firm also exceeded the industry average cash flow growth rate of -33.39%.
- You can view the full PDL BioPharma Ratings Report.
- Our dividend calendar.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts